PDCD1 and nonpapillary renal cell carcinoma: ccRCC patients are mainly of immune infiltrating type (73%), enriched with antitumor M1 macrophages, activated CD4+ memory T cells, and activated NK cells, but the immune contexture failed to accurately predict the efficacy of anti-PD-1 therapy and mTOR inhibitors (Braun et al., 2020).